Gene Therapy Programs
Unspecified
Pre-clinicalActive
Key Facts
About Ibex Biosciences
Ibex Biosciences is a private, pre-clinical biotech firm pursuing a multi-platform strategy in antibodies, gene therapy, and regenerative medicine. The company leverages its internal discovery capabilities, highlighted by its CSO's background in phage display technology, to build a wholly-owned pipeline targeting oncology, infectious disease, and inflammatory conditions. Currently in a pre-revenue stage, Ibex is actively seeking investment through a Regulation D 506(c) offering to advance its programs. Its management team brings decades of experience in preclinical research, gene therapy, and business development.
View full company profileTherapeutic Areas
Other Unspecified Drugs
| Drug | Company | Phase |
|---|---|---|
| Exosome-based Diagnostics | EriVan Bio | Pre-clinical |
| Novel Delivery Sprays & Oral Forms | Navinta | Development/NDA Filing |
| Regenerative Medicine Platform | Ibex Biosciences | Pre-clinical |